These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 9620105

  • 1. Troglitazone in type II diabetes mellitus.
    Sparano N, Seaton TL.
    Pharmacotherapy; 1998; 18(3):539-48. PubMed ID: 9620105
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
    Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI.
    N Engl J Med; 1998 Mar 26; 338(13):867-72. PubMed ID: 9516221
    [Abstract] [Full Text] [Related]

  • 6. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, Foot E, Seghieri G, Ferrannini E.
    Clin Pharmacol Ther; 1997 Aug 26; 62(2):194-202. PubMed ID: 9284856
    [Abstract] [Full Text] [Related]

  • 7. The role of troglitazone in treating the insulin resistance syndrome.
    Granberry MC, Schneider EF, Fonseca VA.
    Pharmacotherapy; 1998 Aug 26; 18(5):973-87. PubMed ID: 9758309
    [Abstract] [Full Text] [Related]

  • 8. New oral therapies for type 2 diabetes.
    Purnell JQ, Hirsch IB.
    Am Fam Physician; 1997 Nov 01; 56(7):1835-42. PubMed ID: 9371013
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
    Katoh S, Hata S, Matsushima M, Ikemoto S, Inoue Y, Yokoyama J, Tajima N.
    Metabolism; 2001 Apr 01; 50(4):414-7. PubMed ID: 11288035
    [Abstract] [Full Text] [Related]

  • 11. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
    Johnson MD, Campbell LK, Campbell RK.
    Ann Pharmacother; 1998 Mar 01; 32(3):337-48. PubMed ID: 9533065
    [Abstract] [Full Text] [Related]

  • 12. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
    Plosker GL, Faulds D.
    Drugs; 1999 Mar 01; 57(3):409-38. PubMed ID: 10193691
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rosiglitazone.
    Goldstein BJ.
    Int J Clin Pract; 2000 Jun 01; 54(5):333-7. PubMed ID: 10954962
    [Abstract] [Full Text] [Related]

  • 15. Troglitazone.
    Spencer CM, Markham A.
    Drugs; 1997 Jul 01; 54(1):89-101; discussion 102. PubMed ID: 9211083
    [Abstract] [Full Text] [Related]

  • 16. Repaglinide in combination therapy.
    Moses R.
    Diabetes Nutr Metab; 2002 Dec 01; 15(6 Suppl):33-8. PubMed ID: 12702006
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
    Scheen AJ, Lefèbvre PJ.
    Diabetes Care; 1999 Sep 01; 22(9):1568-77. PubMed ID: 10480527
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus.
    Parker JC.
    Adv Drug Deliv Rev; 2002 Nov 05; 54(9):1173-97. PubMed ID: 12393300
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.